- 101. Drug allergy
- (UMLS (HL7) C1548333) =Immunologic Factor =Allergen Type;
| - 151. drug interaction
- [physical chemical interaction between drugs and other compounds, including other drugs, particularly in biological systems. ( CSP )] (UMLS (CSP) C0687133) =Molecular Function =physical chemical interaction;
=nutrient drug interaction |
- 102. DRUG ALLERGY NEC
- (UMLS (ICD9CM) C1719669) Other drug allergy =Disease or Syndrome
| - 152. Drug Interaction Alert
- [Proposed therapy may interact with an existing or recent drug therapy ( HL7V3.0 )] (UMLS (HL7) C1553528) =Intellectual Product =Therapeutic Product Alert;
|
- 103. drug biological activity
- [ ] (UMLS (CSP) C0599112) =Functional Concept
| - 153. Drug interference
- (UMLS (HL7) C1547774) =Idea or Concept =HL7 Vocabulary Version 2.5;
|
- 104. drug biological half life
- [ ] (UMLS (CSP) C0599113) =Temporal Concept
| - 154. drug intolerance
- [Hypersensitivity resulting in an adverse reaction upon exposure to a drug. ( HL7V3.0 )] (UMLS (CSP) C0277585) =Pathologic Function =intolerance;
=drug allergy;
Drug Non-Allergy Intolerance;
|
- 105. drug carcinogenesis
- [process by which normal cells are transformed into cancer cells by means of a drug. ( CSP )] (UMLS (CSP) C0596466) =Neoplastic Process =Cancer Induction;
| - 155. drug intolerant
- [ ] (UMLS (CSP) C0599741) =Finding ;
|
- 106. drug classification
- [systematic arrangement of drugs into categories or classes based on common characteristics such as properties, structure, function, usage, etc. ( CSP )] (UMLS (CSP) C0596463) =Intellectual Product =Pharmacologic;
classification | - 156. drug invoice group
- [A grouping of invoice element details including the one specifying the drug being invoiced. It may also contain generic detail items such as markup. ( HL7V3.0 )] (UMLS (HL7) C1555661) =Intellectual Product =ActInvoiceInterGroupCode;
|
- 107. drug clearance
- [ ] (UMLS (CSP) C0683151) =Physiologic Function ;
| - 157. drug isolation
- [ ] (UMLS (CSP) C0920473) =Research Activity
|
- 108. Drug Company
- [A company licensed to discover, develop, market and distribute drugs. ( NCI )] (UMLS (NCI) C0815266) Pharmaceutical Company;
=Health Care Related Organization ;
| - 158. drug legislation
- [Laws concerned with manufacturing, dispensing, and marketing of drugs. ( MSH )] (UMLS (CSP) C0023255) =Regulation or Law
|
- 109. drug control
- [control of drug and narcotic use by international agreement, or by institutional systems for handling prescribed drugs; includes regulations concerned with the manufacturing, dispensing, approval, and marketing of drugs. ( CSP )] (UMLS (CSP) C0013168) =Governmental or Regulatory Activity =legal/correctional;
=drug detection | - 159. drug leukemogenesis
- [ ] (UMLS (CSP) C0598329) =Neoplastic Process
|
- 110. drug craving
- [ ] (UMLS (CSP) C0556446) =Finding
| - 160. drug maintenance
- [ ] (UMLS (CSP) C0598144) =Therapeutic or Preventive Procedure ;
|
- 111. DRUG DEPEND NEC-CONTIN
- [ ] (UMLS (ICD9CM) C0338738) =Mental or Behavioral Dysfunction
| - 161. drug mechanism
- [ ] (UMLS (CSP) C0920474) =Pathologic Function
|
- 112. DRUG DEPEND NEC-EPISODIC
- [ ] (UMLS (ICD9CM) C0338739) =Mental or Behavioral Dysfunction
| - 162. DRUG MENTAL DISORDER NEC
- [ ] (UMLS (ICD9CM) C0154325) =Mental or Behavioral Dysfunction
|
- 113. DRUG DEPEND NEC-IN REM
- [ ] (UMLS (ICD9CM) C0154500) =Mental or Behavioral Dysfunction
| - 163. DRUG MENTAL DISORDER NOS
- [ ] (UMLS (ICD9CM) C0154330) =Mental or Behavioral Dysfunction
|
- 114. DRUG DEPEND NEC-UNSPEC
- [ ] (UMLS (ICD9CM) C0029792) =Mental or Behavioral Dysfunction ;
| - 164. drug metabolism
- [the buildup and breakdown of drugs for utilization by the organism. ( CSP )] (UMLS (CSP) C0683140) =Molecular Function ;
=Intermediary Metabolism;
mechanism of action |
- 115. DRUG DEPEND NOS-CONTIN
- [ ] (UMLS (ICD9CM) C0154509) =Mental or Behavioral Dysfunction
| - 165. drug modification
- [ ] (UMLS (CSP) C0598331) =Biomedical Occupation or Discipline
|
- 116. DRUG DEPEND NOS-EPISODIC
- [ ] (UMLS (ICD9CM) C0154510) =Mental or Behavioral Dysfunction
| - 166. Drug Modulation
- (UMLS (NCI) C0279532) =Therapeutic or Preventive Procedure
|
- 117. DRUG DEPEND NOS-REMISS
- [ ] (UMLS (ICD9CM) C0154511) =Mental or Behavioral Dysfunction
| - 167. Drug Non-Allergy Intolerance
- [Hypersensitivity to an agent caused by a mechanism other than an immunologic response to an initial exposure ( HL7V3.0 )] (UMLS (HL7) C1699571) =Clinical Attribute ;
=drug intolerance;
Non-Allergy Intolerance |
- 118. DRUG DEPEND NOS-UNSPEC
- [ ] (UMLS (ICD9CM) C0375178) =Mental or Behavioral Dysfunction
| - 168. DRUG PERSIST AMNESTC DIS
- [ ] (UMLS (ICD9CM) C1456289) Drug-induced persisting amnestic disorder;
=Disease or Syndrome |
- 119. DRUG DEPEND PREG-UNSPEC
- [ ] (UMLS (ICD9CM) C0269685) =Mental or Behavioral Dysfunction
| - 169. DRUG PERSISTING DEMENTIA
- [ ] (UMLS (ICD9CM) C1456288) Drug-induced persisting dementia;
=Mental or Behavioral Dysfunction |
- 120. Drug dependence of mother, with delivery
- [ ] (UMLS (ICD9CM) C0156850) =Mental or Behavioral Dysfunction
| - 170. drug preservation
- [preventing drugs or pharmaceuticals from decay, separation, being rendered useless, or extending the shelf life of drugs by means of a chemical agent, cooling, or other physical process. ( CSP )] (UMLS (CSP) C0728909) =Laboratory Procedure =preservation;
|
- 121. Drug dependence of mother, with delivery, with mention of postpartum complication
- [ ] (UMLS (ICD9CM) C0156851) =Mental or Behavioral Dysfunction
| - 171. Drug Preservative
- [Chemicals that are added to drug products to prolong shelf life and maintain sterility. Protection of formulations, especially aqueous solutions, against microbial growth requires use of either antibacterial or antifungal preservatives. Generally, such agents are active against either bacteria or fungi but a few are active against both. The antimicrobials include but not limited to chlorobutanol, benzyl alcohol, sodium benzoate, sorbic acid, and phenol. The antioxidizing agents include butylated hydroxytolune, hydroxyanisole, propyl gallate, and sulfites. The necessary addition of preservatives for both safety and economy sometimes has been associated with significant adverse effects in certain patient populations. ( NCI )] (UMLS (NCI) C0033086) =Biomedical or Dental Material ;
=inactive ingredient;
|
- 122. Drug dependence, antepartum
- [ ] (UMLS (ICD9CM) C0156852) =Mental or Behavioral Dysfunction
| - 172. drug production
- [ ] (UMLS (CSP) C0920698) =Biomedical Occupation or Discipline
|
- 123. Drug dependence, postpartum
- [ ] (UMLS (ICD9CM) C0156853) =Mental or Behavioral Dysfunction
| - 173. DRUG PSY DIS W HALLUCIN
- [ ] (UMLS (ICD9CM) C1456732) Drug-induced psychotic disorder with hallucinations;
=Mental or Behavioral Dysfunction ;
|
- 124. drug design
- [The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include pharmacokinetics, dosage analysis, or drug administration analysis. ( MSH )] (UMLS (CSP) C0013171) =Occupation or Discipline
| - 174. DRUG PSYCH DISOR W DELUS
- [ ] (UMLS (ICD9CM) C1456286) Drug-induced psychotic disorder with delusions;
=Mental or Behavioral Dysfunction |
- 125. drug design/synthesis/production
- [drug (or potential drug) synthesis or development; includes production of drugs, hormones, and related chemicals; some projects may include DRUG DISCOVERY/ISOLATION; for development of non-drug substances such as radiotracers see TECHNOLOGY/TECHNIQUE DEVELOPMENT. ( CSP )] (UMLS (CSP) C0178604) =Phenomenon or Process =biomedical resource;
technology/technique development =drug screening/evaluation;
orphan disease/drug;
drug quality/standard;
drug discovery/isolation;
| - 175. drug quality
- [ ] (UMLS (CSP) C0920475) =Intellectual Product
|
- 126. drug detection
- [procedures to detect the presence of drugs or their side products in blood, urine, breath, or other biological samples; do not confuse with DRUG SCREENING/EVALUATION. ( CSP )] (UMLS (CSP) C0038577) =Laboratory Procedure ;
=drug control;
evaluation/testing | - 176. drug quality/standard
- [levels of excellence which characterize drugs based on accepted standards of quality; standards of adequacy, acceptable performance, identification, quality and potency. ( CSP )] (UMLS (CSP) C0596464) =Intellectual Product =drug design/synthesis/production;
chemical standardization |
- 127. DRUG DETOXIFICATION
- [ ] (UMLS (ICD9CM) C0204600) =Therapeutic or Preventive Procedure
| - 177. Drug reactions and intoxications specific to newborn
- [ ] (UMLS (ICD9CM) C0270275) =Injury or Poisoning
|
- 128. drug development
- [Design, identification, synthesis, extraction, purification, modification, or characterization of potential anticancer agents; studies of their metabolism, distribution, excretion, physiological effects, molecular interactions, structural analysis, toxicity, mechanism of action, antitumor effects in vivo (nonhuman species) or in vitro (human or nonhuman), and phase I and phase II clinical trials. ( NCI )] (UMLS (CSP) C0872152) =Biomedical Occupation or Discipline ;
| - 178. drug receptor
- [proteins that bind specific drugs with high affinity and trigger intracellular changes influencing the behavior of cells; generally thought to be receptors for some endogenous substances not otherwise specified; postcoordinate with specific drug terms if needed. ( CSP )] (UMLS (CSP) C0034799) =Amino Acid, Peptide, or Protein; Receptor ;
=Receptor;
=opiate receptor;
cannabinoid receptor;
PCP receptor;
benzodiazepine receptor;
|
- 129. drug discovery
- [ ] (UMLS (CSP) C0920472) =Research Activity
| - 179. drug registry
- [ ] (UMLS (CSP) C0920476) =Intellectual Product
|
- 130. drug discovery/isolation
- [identification of naturally-derived or synthetic compounds with therapeutic potential. ( CSP )] (UMLS (CSP) C0872033) =Research Activity ;
=drug design/synthesis/production;
| - 180. drug regulation
- [ ] (UMLS (CSP) C0013201) =Regulation or Law
|
- 131. drug discrimination
- [ ] (UMLS (CSP) C0679080) =Idea or Concept ;
| - 181. Drug Rehab
- [Provision of treatment for drug abuse. ( HL7V3.0 )] (UMLS (HL7) C1555458) =Intellectual Product =ActMedicalServiceCode;
|
- 132. drug efficacy
- [ ] (UMLS (CSP) C0598333) =Qualitative Concept
| - 182. DRUG REHAB/DETOX
- (UMLS (ICD9CM) C0204602) =Therapeutic or Preventive Procedure
|
- 133. Drug Enforcement Administration registration number
- (UMLS (HL7) C1549689) =Intellectual Product =Identifier type;
| - 183. DRUG REHABILITATION
- [ ] (UMLS (ICD9CM) C0204601) =Therapeutic or Preventive Procedure
|
- 134. Drug Enforcement Agency
- (UMLS (HL7) C1549052) =Organization =Organization, agency, department;
| - 184. drug related cancer
- [ ] (UMLS (CSP) C0920477) =Neoplastic Process
|
- 135. Drug Enforcement Agency no.
- (UMLS (HL7) C1548637) =Intellectual Product =Practitioner ID number type;
| - 185. drug related diabetes mellitus
- [diabetes mellitus caused by medicinal substances given to or taken by the patient; concept excludes diabetes resulting from exposure to nonmedicinal chemicals in the environment or drugs of abuse, for which see TOXICOLOGY. ( CSP )] (UMLS (CSP) C0271646) =Disease or Syndrome =Diabete mellito;
drug adverse effect |
- 136. drug evaluation
- [Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. ( MSH )] (UMLS (CSP) C0013175) =Research Activity
| - 186. drug related neoplasm
- [ ] (UMLS (CSP) C0920478) =Neoplastic Process
|
- 137. Drug Excipient
- [Any intentionally added component of a finished pharmaceutical product other than the claimed therapeutic or diagnostic ingredient(s). The excipients are added to facilitate administration or manufacture, improve product delivery, promote the consistent release and bioavailability of the drug, enhance stability, assist in product identification, or enhance other product characteristics. Pharmaceutical excipients do not affect therapeutic effects of the preparation or suitable tests or assays. The term does not apply to macromolecular compounds like albumin, or compounds like amino acids and sugars that are used in biological products, nor does it apply to process or product-related impurities (e.g. degradation products, residual solvents), or extraneous contaminants. ( NCI )] (UMLS (NCI) C0015237) =Biomedical or Dental Material ;
| - 187. drug related neoplasm/cancer
- [neoplasm or cancer caused or exacerbated by medicinal substances given to or taken by the patient; concept excludes neoplasms or cancer resulting from exposure to nonmedicinal chemicals in the environment or drugs of abuse, for which see TOXICOLOGY or CHEMICAL RELATED NEOPLASM/CANCER. ( CSP )] (UMLS (CSP) C0872034) =Neoplastic Process ;
=drug adverse effect;
chemical related neoplasm/cancer |
- 138. Drug Exposure
- [The term describes the situation in which a constant drug dose elicits increasing effects.The condition is opposite to drug tolerance since less dose of the substance is required to reinstate the initial effect (reverse-tolerance). The concept does not refer to cumulative drug effect. ( NCI )] (UMLS (NCI) C0743284) =Finding ;
| - 188. drug resistance
- [tendency of biological systems (organisms, cells, or cell-free systems) to fail to respond as expected to drug treatment or exposure; may be due to specific enzymes, transporters, or receptors which block drug action. ( CSP )] (UMLS (CSP) C0013203) =Biologic Function =Pharmacologic;
=MDR;
pesticide resistance;
insulin sensitivity/resistance;
|
- 139. Drug Extravasation
- [Leakage of drug from a vein into the surrounding tissue. ( NCI )] (UMLS (NCI) C0280952) =Injury or Poisoning
| - 189. Drug Resistance Inhibition Treatment
- [Treatment used to make cancer cells less resistant to anticancer drugs. ( NCI )] (UMLS (NCI) C0677911) =Therapeutic or Preventive Procedure ;
|
- 140. drug extravasation management
- (UMLS (NCI) C0280283) =Therapeutic or Preventive Procedure
| - 190. drug resource
- [ ] (UMLS (CSP) C0920699) =Intellectual Product
|
- 141. Drug Formulation
- [The act or process of developing or preparing a mixture of ingredients to create a desired end drug product, such as a specific flavor, aroma, or polymer; or the desired final drug product itself; also, a listing of the ingredients and composition of the dosage form. ( NCI )] (UMLS (NCI) C0524527) =Research Activity
| - 191. drug screening
- [Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. ( MSH )] (UMLS (CSP) C0013206) =Research Activity
|
- 142. Drug Furnishing or prescriptive authority Number
- (UMLS (HL7) C1549690) =Intellectual Product =Identifier type;
| - 192. Drug Screening
- (UMLS (HL7) C1548848) =Health Care Activity =Consent Type;
|
- 143. drug habituation
- [process whereby an individual's response to a drug lessens with repeated use. ( CSP )] (UMLS (CSP) C0013170) =Mental or Behavioral Dysfunction =behavioral habituation/sensitization;
substance abuse related disorder | - 193. drug screening/evaluation
- [testing and evaluation of the safety, efficacy, and dosage parameters of drugs; do not confuse with DRUG DETECTION. ( CSP )] (UMLS (CSP) C0178605) =Research Activity =drug design/synthesis/production;
evaluation/testing =Placebo |
- 144. drug induced behavior
- [ ] (UMLS (CSP) C0872153) =Individual Behavior ;
| - 194. drug seeking behavior
- [ ] (UMLS (CSP) C0694536) =Individual Behavior
|
- 145. drug induced congenital disorder
- [ ] (UMLS (CSP) C0870452) drug related congenital disorder =Congenital Abnormality; Disease or Syndrome
| - 195. drug sensitivity
- [ ] (UMLS (CSP) C0237865) =Organism Attribute
|
- 146. drug induced lupus
- [ ] (UMLS (CSP) C0263591) =Disease or Syndrome
| - 196. Drug Sensitization
- [The term describes the situation in which a constant drug dose elicits increasing effects.The condition is opposite to drug tolerance since less dose of the substance is required to reinstate the initial effect (reverse-tolerance). The concept does not refer to cumulative drug effect. ( NCI )] (UMLS (NCI) C0475453) =Therapeutic or Preventive Procedure ;
|
- 147. DRUG INDUCED MYOTONIA
- [ ] (UMLS (ICD9CM) C1404542) Drug-induced myotonia;
=Pathologic Function ;
| - 197. drug standard
- [ ] (UMLS (CSP) C0920479) =Intellectual Product
|
- 148. DRUG INDUCED NEUTROPENIA
- [ ] (UMLS (ICD9CM) C0272178) =Disease or Syndrome
| - 198. drug storage
- [ ] (UMLS (CSP) C0013211) =Therapeutic or Preventive Procedure
|
- 149. DRUG INDUCED SLEEP DISOR
- [ ] (UMLS (ICD9CM) C1456292) Drug induced sleep disorders;
=Mental or Behavioral Dysfunction | - 199. drug structure
- [ ] (UMLS (CSP) C1328874) =Intellectual Product; ;
|
- 150. drug information system
- [Information systems, usually computer-assisted, designed to store, manipulate, and retrieve information for planning, organizing, directing, and controlling administrative activities associated with the provision and utilization of clinical pharmacy services. ( MSH )] (UMLS (CSP) C0079133) =Manufactured Object; Intellectual Product ;
| - 200. drug structure function
- [ ] (UMLS (CSP) C1328875) =Qualitative Concept; ;
|
home
